Sorry, let me rephrase my question.
How does SM6 compare to some of the other antibodies in clinical phase for the treatment of MM? Why would Onyx choose SM6 over any of the other antibodies?
The tablet below is a list of Antibodies in development/clinical study for the Tx of MM.
Reference (informative reading material): http://www.klinikum.uni-heidelberg.de/fileadmin/medizinische_klinik/Abteilung_5/images/Veranstaltungen/MM_Workshop_2013/Samstag/Raab_HMW2013.pdf
why onyx sees the opportunity - deja vu ?, page-5
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(12.5%) |
Mkt cap ! $7.201M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $564 | 161.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 29348732 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 26555626 | 17 |
View Market Depth
| Last trade - 12.59pm 18/10/2024 (20 minute delay) ? |
| PAB (ASX) Chart |